Epitope-Engineered Human Hematopoietic Stem Cells Are Shielded from CD123-Targeted Immunotherapy

Scientists demonstrated that epitope-engineered HSPCs were shielded from CD123-targeted immunotherapy but remained functional, while CD123-deficient HSPCs displayed a competitive disadvantage.